USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ONCOGENE SCIENCE, INC.
City: Uniondale
State: NY
Zip+4: 11553
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,715,413.00 47
SBIR Phase II $7,627,997.00 15

Award List:

DNA PROBES FOR DETECTION OF CHROMOSOMAL TRANSLOCATIONS

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nora C. Heisterkamp , Principal Investigator
Award Amount: $48,140.00

RECEPTOR

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: John r stephenson , PRINCIPAL INVESTIGATOR
Award Amount: $45,000.00
Abstract:
The epidermal growth factor receptor is a 170,000 dalton glycoprotein composed of three domains. the cell surface domain binds epidermal growth factor (egf) and a low molecular weight, tumor-specific growth factor (tgf alpha). autocrine stimulation of the egf receptor occurs when the same tumor cell… More

PROTEIN KINASE C IS ACTIVATED BY TUMOR PROMOTORS AND THERE IS STRONG EVIDENCE THAT IT ACTUALLY MEDIATES TUMOR PROMOTION.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Fred h reynolds jr , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Protein kinase c is activated by tumor promotors and there is strong evidence that it actually mediates tumor promotion. activated protein kinase c phosphorylates the epidermal growth factor receptor guanylate cyclase and several other potentially regulatory proteins; the physiological significance… More

IMMUNOLOGIC ASSAY FOR THE PHILADELPHIA TRANSLOCATION

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dr Eleonora Heisterkamp, Principal Investigator – (516) 877-2882
Award Amount: $48,000.00

DNA PROBE ASSAY FOR THE PHILADELPHIA TRANSLOCATION

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Groffen , Principal Investigator
Award Amount: $45,000.00

DNA PROBES FOR DETECTION OF CHROMOSOMAL TRANSLOCATIONS

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Nora C. Heisterkamp , Principal Investigator
Award Amount: $250,000.00
Abstract:
A specific chromosomal translocation, the philadelphia translocation, is characteristic of over 96% of patients with chronic myelocytic leukemia. this translocation involves the transfer of the c-abl oncogene from chromosome 9 to a specific region, designated the breakpoint cluster region (bcr), on… More

IMMUNOLOGIC ASSAY FOR THE PHILADELPHIA TRANSLOCATION

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency: HHS
Principal Investigator: Dr Eleonora Heisterkamp , Principal Investigator
Award Amount: $492,000.00
Abstract:
Over 96 percent of all chronic myelogenous leukemia (cml) and 17 to 25 percent of all acute lymphoblastic leukemia patients have a philadelphia (ph') chromosome in their leukemic cells. as the presence of the ph' chromosome has prognostic and diagnostic implications, cytogenetical analysis is… More

PURIFICATION OF HUMAN PLATELET DERIVED GROWTH FACTOR RECEPTOR

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The two most prevalent causes of death in western civilization are myocardial and cerebral infarcations. these conditions are primarily the result of atheroscleroticlesions which the blood vessels supplying the heart and brain. considerable evidence has now accumulated which suggest that… More

IMMUNOASSAY TO MONITOR EGF LEVELS IN HUMAN PREGNANCY

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Epidermal growth factor (egf) is a potent mitogen for a variety of cell types both in vitro and in vivo. recent studies have suggested that egf may play a role in the maintenance of normal pregnancy in mice. removal of the submandibular gland of pregestational mice attenuates the normal rise in… More

CHARACTERIZATION OF SRC KINASE ACTIVATION IN COLON TUMORS.

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
A recent study has reported elevated levels of p60(c-src) protein-tyrosine kinase specific activity in 100% of human colon carcinoma tumor tissues and cell lines examined (1). four mechanisms could account for this activation: i) a point mutation at several sites in the amino terminal half of the… More

PDGF-RECEPTOR KINASE INHIBITORS FOR ATHEROSCLEROSIS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator: J Gordon Foulkes
Award Amount: $49,470.00

DNA PROBE ASSAY FOR THE PHILADELPHIA TRANSLOCATION

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency: HHS
Principal Investigator: John Groffen , Principal Investigator
Award Amount: $500,000.00
Abstract:
Leukemic cells of approximately 96 percent of patients with chronic myelogenous leukemia (cml) and 10 to 25 percent of acute lymphocytic leukemia (all) patients are characterized by a marker chromosome. this chromosome, designated the philadelphia (ph') chromosome, is the result of a… More

YEAST MRNA 3' END FORMATION AS AN ANTIFUNGAL DRUG TARGET

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $49,354.00
Abstract:
The formation of polyadenylated 3'-termini is an essential step in the biogenesis of eukaryotic mrna. in vertebrates, the consensus aauaaa and other sequences have been identified as requirements for correct 3'-end formation. in yeast, only half of all genes have a recognizable aauaaa consensus, and… More

ANTIBODIES TO ACTIVATED MUTANT RAS ONCOGENE PROTEINS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

EUKARYOTIC EXPRESSION OF TRANSFORMING GROWTH FACTOR B3

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

CHARACTERIZATION OF P60C-SRC BINDING TO MEMBRANES

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Colin Goddard
Award Amount: $49,945.00
Abstract:
Human colon carcinoma cell lines have been shown to posses elevated levels of specific p60c-src protein-tyrosine kinaseactivity when compared to control colon lines. two parameters appear to be essential for transformation by p60c-src: (1) the presence of an active protein tyrosine kinase, and (2)… More

PDGF-RECEPTOR KINASE INHIBITORS FOR ATHEROSCLEROSIS

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: HHS
Principal Investigator: J Gordon Foulkes
Award Amount: $480,687.00
Abstract:
The two most prevalent causes of death in western civilization are myocardial and cerebral infarctions, conditions that are primarily the result of atherosclerotic lesions within the blood vessels supplying the heart and brain. evidence suggests that platelet-derived growht factor (pdgf) stimulates… More

NEW TARGETS IN ASTHMA THERAPY: BETA-ADRENERGIC RECEPTOR KINASE

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Colin Goddard
Award Amount: $50,000.00
Abstract:
Beta-adrenergic agonists are used in the treatment of chronic and exercise-induced asthma. these agents work through the beta-adrenergic receptor/adenylate cyclase-coupled effector system, producing relaxation of thesmooth muscle of the trachea and bronchial tree, and thereby relieving asthmatic… More

THE DISCOVERY OF NOVEL CHOLESTEROL-LOWERING DRUGS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alexander Stewart
Award Amount: $49,667.00

EUKARYOTIC EXPRESSION OF TRANSFORMING GROWTH FACTOR B3

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $184,345.00
Abstract:
Transforming growth factors type beta (tgf-beta's) are proteins of 25 kd disulfide-linked homodimers and heterodimers that act to control the proliferation of a variety of both normal and transformed cell types. in addition, tgf-beta's have been shown to stimulate wound healing and to act as potent… More

ANTIBODIES TO ACTIVATED MUTANT RAS ONCOGENE PROTEINS

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $499,501.00
Abstract:
Activated ras oncogenes have been identified in a significant percentage of cancers, including leukemias and carcinomas of the colon, pancreas, and lung. high-affinity antibodies reactive with both normal and activated human p21ras are available. however, previous attempts to developantibodies… More

DETECTING PROTEIN INTERACTIONS BY A YEAST GENETIC SYSTEM

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Baronas-lowell, Diane M , Principal Investigator
Award Amount: $40,001.00
Abstract:
Specific protein- protein interactions are central to many cellular functions. detection of these interactions has generally been by co-immunoprecipitation analyses. these methods have drawbacks deriving from the nature of this technique, including the difficulty of cloning gene sequences for newly… More

TRANSCRIPTIONAL CONTROL OF THE EGF RECEPTOR GENE

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Haley, John D , Principal Investigator
Award Amount: $49,313.00
Abstract:
Abnormalities of the epidermal growth factor receptor (egfr) appear to be associated with a variety of proliferative diseases. in human carcinoma biopsy specimens, overexpression of egfr is frequently observed to occur in the absence of gene amplification. in psoriatic epidermis, autocrine… More

A NOVEL ASSAY TO DETECT TRANSLOCATION IN LEUKEMIAS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yanez, Luis , Principal Investigator
Award Amount: $50,000.00
Abstract:
Several chromosomal translocations associated with different types of leukemias have been recently characterized. as a result of these translocations, new mrna species are produced, coding for novel fusion proteins. the goal of phase i is to develop a panel of non-isotopic assays to detect t(1;19)… More

TRANSCRIPTIONAL CONTROL OF THE ERYTHROPOIETIN GENE

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Case, Casey C , Principal Investigator
Award Amount: $47,944.00

DEVELOPMENT OF GROWTH HORMONE RELEASING FACTOR AGONISTS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Haley, John D , Principal Investigator
Award Amount: $49,919.00

TRANSCRIPTIONAL INHIBITION OF THE SCAVENGER RECEPTOR

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Case, Casey C , Principal Investigator
Award Amount: $40,320.00

THE DISCOVERY OF NOVEL CHOLESTEROL-LOWERING DRUGS

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alexander Stewart
Award Amount: $478,985.00
Abstract:
The two most prevalent causes of death in western civilization are myocardial and cerebral infarctions, conditions that are primarily the result of atherosclerotic lesions within the blood vessels supplying the heart and brain. a causal link between hypercholesterolemia due to elevated plasma… More

ACTIVATED PROTEIN KINASE SPECIFIC ANTIBODIES

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Craig M Sorensen
Award Amount: $49,775.00
Abstract:
Protein phosphorylation is the major mechanism for regulation of protein function in eukaryotic cells. over 100 protein kinases have been described, greater than 32 of which are now known to be encoded by oncogenes (1). elevated src and neu protein-tyrosine kinase activity in human colon and breast… More

INHIBITION OF IL-1 DEPENDENT KINASE AND ATHEROGENESIS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alexander Stewart
Award Amount: $30,559.00
Abstract:
The two most prevalent causes of death in western civilization, myocardial and cerebral infarctions, are primarily the result of atherosclerotic lesions. it is clear that uncontrolled proliferation of vascular smooth muscle cells (vsmcs) plays a major role in advanced lesion formation. interleukin-1… More

INHIBITORS OF VEGF-INDUCED ANGIOGENESIS AS ANTI-TUMOR DRUGS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alexander A Stewart
Award Amount: $49,902.00
Abstract:
The growth of solid tumors is dependent on the development of new vasculature for its supply of nutrients and oxygen. tumor cells induce the outgrowth of new capillary vessels by producing diffusible angiogenic factors. in the normal adult, angiogenesis is a process primarily associated with wound… More

AMP-KINASE CASCADE ACTIVATORS AND ATHEROGENESIS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: J Gordon Foulkes
Award Amount: $49,835.00
Abstract:
Myocardial and cerebral infarction, conditions which are primarily the result of atherosclerotic lesions within coronary and cerebral blood vessels, are the leading causes of death in western civilization. a casual link between hypercholesterolemia and the premature development of atherosclerosis is… More

DRUG SCREENING FOR ANTI-METASTATIC COMPOUNDS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: John D Haley
Award Amount: $48,334.00
Abstract:
Metastasis is a complex pathophysiolgical event which involves proteolytic degradation of extracellular matrix components and migration of tumor cells to specific organs located at a distance from the primary tumor. extracellular matrix turnover is controlled by specific metalloproteinases,… More

SEEKING DRUGS THAT INCREASE KIT LIGAND GENE EXPRESSION

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Casey C Case
Award Amount: $49,999.00
Abstract:
The ligand for the c-kit receptor functions as a potent growth factor and differentiation inducer for very early hemotopoietic stem cells. the kit ligand protein is currently being evaluated by several labs for therapeutic utlity in combination with other hematopoietic growth factors for the… More

TRANSLOCATION ASSAY BY PCR AMPLIFICATION IN SITU

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Anilkumar Dhundale
Award Amount: $48,557.00
Abstract:
Polymerase chain reaction (pcr) amplification and detection in sity has been described for the human papillomavirus (hpv 16, 1) and visna virus (2). use of pcr techniques is extremely powerful yet has some disadvantages. pcr amplification in situ circumvents some of these and also allows correlation… More

MUTANT P53 PROTEINS IN CANCER PATIENT AND NORMAL SERA

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frederick H Reynolds
Award Amount: $50,000.00
Abstract:
P53 is a negative regulator of cell division. mutations in p53 are far and away the most frequent genetic lesions encountered in human cancers, appearing in 50% or more of tumors analyzed. these findings raise the intriguing possibility that mutant p53 could be useful marker for human cancers. we… More

INHIBITION OF MCP-1 GENE EXPRESSION AND ALTHEROGENESIS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Casey C Case
Award Amount: $46,059.00

TRANSCRIPTIONAL CONTROL OF THE ERYTHROPOIETIN GENE

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Case, Casey C , Principal Investigator
Award Amount: $500,000.00
Abstract:
Erythropoietin (epo) induces erythroid progenitor cells to differentiate into erythrocytes. recombinant epo is approved for treating anemia in patients with chronic renal failure, and is being evaluated in anemias associated with chemotherapy, aids and surgery. however, the use of recombinant epo as… More

DEVELOPMENT OF GROWTH HORMONE RELEASING FACTOR AGONISTS

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Haley, John D , Principal Investigator
Award Amount: $499,577.00
Abstract:
Human growth hormone (hgh) is a major regulator of growth and metabolism. recombinant hgh has been used to correct pituitary dwarfism. recently, recombinant hgh has been shown to counteract various degenerative processes associated with aging. other potential uses include treatment of obesity and… More

TRANSCRIPTIONAL INHIBITION OF THE SCAVENGER RECEPTOR

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Case, Casey C , Principal Investigator
Award Amount: $500,000.00
Abstract:
Advanced cardiovascular disease is frequently associated with large complex atherosclerotic lesions or atheromas. these lesions, which are first characterized as fatty streaks in the arterial wall, contain cholesterol laden cells derived from macrophages ("foam cells"). macrophages appear to convert… More

INHIBITION OF MCP-1 GENE EXPRESSION AND ALTHEROGENESIS

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Casey C Case
Award Amount: $345,161.00
Abstract:
The two most prevalent causes of death in western civilization, myocardial and cerebral infarctions, are primarily the result of atherosclerotic lesions. two major contributing factors to lesion formation are the accumulation of cholesterol-ester-rich macrophage-derived 'foam cells,' and… More

Detection of Altered APC Proteins in Colon Cancer Cells

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: David E. Hill
Award Amount: $49,957.00
Abstract:
Mutations in the APC gene appear to be crucial for adenoma formation in inherited Familial Adenomatous Polyposis (FAP) and in the early stages of colorectal cancer. Analysis of the APC gene has identified mutations in germ line DNA of FAP patients. Over 90% of the mutations interrupt the reading… More

Immunometric Assay for Activated Kinases

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Craig M. Sorensen
Award Amount: $49,999.00
Abstract:
Increased phosphorylation of receptor protein-tyrosine kinases has been implicated in different carcinomas. In these cancers the degree of amplification appears to correlate with the prognosis: the greater the amplification the worse the prognosis. What is unclear is whether overall kinase… More

Histochemical Assay for Activated Protein Kinases

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Craig M. Sorensen
Award Amount: $50,000.00
Abstract:
Increased phosphorylation of receptor protein-tyrosine kinases has been implicated in different carcinomas. In these cancers the degree of amplification appears to correlate with the prognosis: the greater the amplification the worse the prognosis. It is unclear whether overall kinase amplification… More

Development of an ELISA for Pro-Cathepsin D.

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: James R. Zabrecky
Award Amount: $50,000.00
Abstract:
There is mounting evidence that the over-production of the lysosomal enzyme, Cathepsin D, can be a useful prognostic marker in breast cancer. Cathepsin D is synthesized as a 52 kDa precursor (pro-CD)) that is processed into the active mature form made up of 34k and 14k subunits. Although pro-CD is… More

Truncated Forms of EGFR in Breast Cancer Patients

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: James R. Zabrecky
Award Amount: $49,907.00
Abstract:
Studies have shown that the Epidermal Growth Factor Receptor (EGFr) is overexpressed in 30-50% of breast carcinomas and that overexpression correlates with poor patient prognosis. Recent studies suggest that EGFr positivity may be predictive of poor patient response to endocrine therapy. Studies… More

Inhibition of The HIV-1 REV Transactivator

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Anilkumar R. Dhundale
Award Amount: $49,767.00

Fetal HB Gene for Sickle Cell and Beta-Thalassemia

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: John D. Haley
Award Amount: $49,690.00

Discovery of New Chemical Entities that Inhibit NEF

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Adriana Heguy
Award Amount: $81,000.00
Abstract:
We will identify compounds which inhibit the function(s) of the human immunodeficiency virus(HIV) accessory protein Nef. In vivo experiments in rhesus monkeys indicate that the simianimmunodeficiency virus (SIV) nef is critical pathogenic determinant of this virus. It has recently beenshown that CD4… More

Modulation of BCR/ABL GRB2 Interaction

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kenneth Iwata
Award Amount: $75,000.00
Abstract:
Bcr/Abl is a chimeric oncogene implicated in the pathogenesis of Philadelphia chromosome (Ph1)positive human leukemias. Worldwide there are approximately 60,000 patients with the Bcr/Abltranslocation, with very limited therapy available. Bone marrow transplantation is the only treatmentthat results… More

Fetal HB Gene for Sickle Cell and Beta-Thalassemia

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: John D. Haley
Award Amount: $688,540.00
Abstract:
The approach of Oncogene Science for the treatment of sickle cell anemia is to identify chemical compounds which elevate transcription of the human fetal globin gene and, thereby, prevent sickle cell anemia or beta-thalassem- ia. Sickle cell disease is an often crippling disease afflicting 1 in 400… More

Thalassemia and B and D Globin Gene Expression

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Haley
Award Amount: $100,000.00
Abstract:
The approach of Oncogene Science for the treatment of beta-thalassemia is to identify chemical compmodulate transcription of the adult beta-globin gene and/or induce expression of the delta-globin geselection is considerably facilitated by the use of highly sophisticated automated facility which… More

Transcriptional Regulation of Thrombopoietin

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Adriana Heguy
Award Amount: $100,000.00
Abstract:
Thrombocytopenia, a condition characterized by low platelet counts and excessive hemorrhage is a pocomplication of many pathological states. The primary and virtually only effective treatment of thiswhole blood or platelet transfusions, the limitations of which are self evident. The humoral… More

Hexokinase II Transcription Activators as Antidiabetics

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alexander Stewart
Award Amount: $100,000.00

Inhibition of The HIV-1 REV Transactivator

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: Anilkumar R. Dhundale
Award Amount: $709,373.00
Abstract:
Acquired Immunodeficiency Syndrome (AIDS), a disease affecting millions of individuals worldwide, has a high incidence of patient mortality. The etiological agent of this disease, the infectious retrovirus HIV-l, has proven refractory to therapeutic intervention. The drugs used in the clinic today… More

SBIR PHASE I: An Ultra-Sensitive mRNA Quantitation Method

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: NSF
Principal Investigator: Anil Dhundale
Award Amount: $75,000.00

ANTIVIRAL STRATEGY DIRECTED TOWARD HCV RNA TRANSLATION

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

MECHANISM--BASED INHIBITORS OF THE HCMV IE86 PROTEIN

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

Hexokinase II Transcription Activators as Antidiabetics

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alexander Stewart
Award Amount: $749,991.00
Abstract:
Impaired insulin-regulated glucose clearance by skeletal muscle is an early event in the developmendependent diabetes mellitus (NIDDM), a potentially lethal condition, which affects over 5 million peof over $20 billion annually in the US alone. Several lines of evidence indicate that reduced… More

INHIBITION OF HIV1 NEF-SH3 INTERACTIONS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Heguy, adriana
Award Amount: $100,000.00

ANTIVIRAL STRATEGY DIRECTED TOWARD HCV RNA TRANSLATION

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $749,837.00

INHIBITION OF HEPATITIS C VIRUS HELICASE

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Cai, Weizhong
Award Amount: $100,000.00